靶点可操作性综述评估CDK4/6作为儿童实体瘤与脑肿瘤治疗靶点
该研究采用靶点可操作性综述(TAR)方法,通过结构化批判性评价系统评估CDK4/6作为儿童实体瘤和脑肿瘤治疗靶点的现有文献证据。分析71篇文献的151条数据条目显示,CDK4/6基因组异常在横纹肌肉瘤、骨肉瘤、高级别胶质瘤、髓母细胞瘤和神经母细胞瘤中频繁出现,但文献未明确CDK4/6异常与化合物疗效之间的相关性。TAR热图支持CDK4/6抑制在尤文肉瘤、髓母细胞瘤、恶性外周神经鞘瘤中的相关性,在神经母细胞瘤、横纹肌肉瘤、横纹肌样瘤和高级别胶质瘤中相关性较低。
要点
- CDK4/6基因组异常在横纹肌肉瘤、骨肉瘤、高级别胶质瘤、髓母细胞瘤和神经母细胞瘤中频繁出现。
- 文献未显示CDK4/6异常与化合物疗效之间存在明确相关性。
- TAR热图支持CDK4/6抑制在尤文肉瘤、髓母细胞瘤、恶性外周神经鞘瘤中的相关性,神经母细胞瘤等中相关性较低。
核心结论
- CDK4/6靶点可操作性综述通过结构化批判性评价显示,CDK4/6基因组异常在多种儿童实体瘤和脑肿瘤中频繁出现,但文献未明确CDK4/6异常与化合物疗效之间的相关性。
- 分析表明若干儿童适应症需要(进一步)临床前评估,以更好地给出建议,尤其涉及肿瘤对CDK4/6的依赖性、预测性生物标志物、耐药机制和联合策略。
- TAR热图支持CDK4/6抑制在尤文肉瘤、髓母细胞瘤、恶性外周神经鞘瘤中的相关性,在神经母细胞瘤、横纹肌肉瘤、横纹肌样瘤和高级别胶质瘤中相关性较低。
研究设计与样本
- 本研究采用靶点可操作性综述(TAR)方法,通过结构化批判性评价评估CDK4/6作为儿童实体瘤和脑肿瘤治疗靶点的现有科学文献。
- 使用PubMed相关检索词,基于相关性标准识别研究儿童实体瘤类型中CDK4/6的原创性出版物。
- 每篇出版物按肿瘤类型标注并分类至不同的概念验证(PoC)数据模块,由两名评价者独立评分,第三名评价者评估并裁定评分差异。
- 分析纳入了71篇出版物的151条数据条目。
主要发现
- CDK4/6基因组异常在横纹肌肉瘤、骨肉瘤、高级别胶质瘤、髓母细胞瘤和神经母细胞瘤中频繁出现。
- 文献未明确显示CDK4/6异常与化合物疗效之间存在明确相关性。
- TAR热图支持CDK4/6抑制在尤文肉瘤、髓母细胞瘤、恶性外周神经鞘瘤中的相关性。
- TAR热图显示CDK4/6抑制在神经母细胞瘤、横纹肌肉瘤、横纹肌样瘤和高级别胶质瘤中相关性较低。
关键数值与推荐
- 每个PoC模块的评分按肿瘤类型取平均值,并在公开可用的R2数据门户中以热图矩阵可视化。
- 交互式热图可通过R2平台访问(r2platform.com/TAR/CDK4_6)。
局限性
- 文献未明确显示CDK4/6异常与化合物疗效之间的相关性。
- 若干儿童适应症需要(进一步)临床前评估,以更好地给出建议,尤其涉及肿瘤对CDK4/6的依赖性、预测性生物标志物、耐药机制和联合策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Childhood cancer is still a leading cause of death around the world. To improve outcomes, there is an urgent need for tailored treatment. The systematic evaluation of existing preclinical data can provide an overview of what is known and identify gaps in the current knowledge. Here, we applied the target actionability review (TAR) methodology to assess the strength and weaknesses of available scientific literature on CDK4/6 as a therapeutic target in paediatric solid and brain tumours by structured critical appraisal. METHODS: Using relevant search terms in PubMed, a list of original publications investigating CDK4/6 in paediatric solid tumour types was identified based on relevancy criteria. Each publication was annotated for the tumour type and categorised into separate proof-of-concept (PoC) data modules. Based on rubrics, quality and experimental outcomes were scored independently by two reviewers. A third reviewer evaluated and adjudicated score discrepancies. Scores for each PoC module were averaged for each tumour type and visualised in a heatmap matrix in the publicly available R2 data portal. RESULTS AND CONCLUSIONS: This CDK4/6 TAR, generated by analysis of 151 data entries from 71 publications, showed frequent genomic aberrations of CDK4/6 in rhabdomyosarcoma, osteosarcoma, high-grade glioma, medulloblastoma, and neuroblastoma. However, a clear correlation between CDK4/6 aberrations and compound efficacy is not coming forth from the literature. Our analysis indicates that several paediatric indications would need (further) preclinical evaluation to allow for better recommendations, especially regarding the dependence of tumours on CDK4/6, predictive biomarkers, resistance mechanisms, and combination strategies. Nevertheless, our TAR heatmap provides support for the relevance of CDK4/6 inhibition in Ewing sarcoma, medulloblastoma, malignant peripheral nerve sheath tumour and to a lesser extent neuroblastoma, rhabdomyosarcoma, rhabdoid tumour and high-grade glioma. The interactive heatmap is accessible through R2 [r2platform.com/TAR/CDK4_6].
引用
- Schubert NA, Chen CY, Rodríguez A, et al. Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours. Eur J Cancer. 2022. PMID: 35671543. doi:10.1016/j.ejca.2022.04.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。